Who Exports Glucosamine from India — 118 Suppliers Behind a $13.3M Market
India's glucosamine export market is supplied by 118 active exporters who collectively shipped $13.3M across 657 shipments. PANACEA BIOTEC PHARMA LIMITED leads with a 13.9% market share, followed by MEDINOMICS HEALTH CARE PRIVATE LIMITED and MEDREICH LIMITED. The top 5 suppliers together control 54.5% of total export value, reflecting a moderately competitive market structure.
Top Glucosamine Exporters from India — Ranked by Export Value
PANACEA BIOTEC PHARMA LIMITED is the leading glucosamine exporter from India, holding a 13.9% share of the $13.3M market across 657 shipments from 118 exporters. The top 5 suppliers — PANACEA BIOTEC PHARMA LIMITED, MEDINOMICS HEALTH CARE PRIVATE LIMITED, MEDREICH LIMITED, AEON FORMULATIONS PRIVATE LIMITED, TROIKAA PHARMACEUTICALS LIMITED — collectively control 54.5% of total export value, indicating a moderately concentrated market. Individual shares are: PANACEA BIOTEC PHARMA LIMITED (13.9%), MEDINOMICS HEALTH CARE PRIVATE LIMITED (13.8%), MEDREICH LIMITED (10.9%), AEON FORMULATIONS PRIVATE LIMITED (8.7%), TROIKAA PHARMACEUTICALS LIMITED (7.1%).
Top Glucosamine Exporters from India
Ranked by export value · 118 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | PANACEA BIOTEC PHARMA LIMITED KONDRO NOVA CAPSULES (GLUCOSAMINE SULPHAKONDRO NOVA CAPSULES GLUCOSAMINE SULPHAKONDRO NOVA CAPUSLES GLUCOSAMINE SULPHA | $1.8M | 1 | 13.9% |
| 2 | MEDINOMICS HEALTH CARE PRIVATE LIMITED ARTHOCARE FORTE CAPLETS (GLUCOSAMINE, CHARTHOCARE FORTEARTHOCARE CAPSULES (GLUCOSAMINE HYDROCHL | $1.8M | 1 | 13.8% |
| 3 | MEDREICH LIMITED GLUCOSAMINE 500MG CAPSULES (CARTIFLEX 50GLUCOSAMINE 500MG CAPSULES CARTIFLEX 50GLUCOSAMINE 500MG CAPSULES 100X10S NOS | $1.4M | 2 | 10.9% |
| 4 | AEON FORMULATIONS PRIVATE LIMITED CARTIFER AV PER TABLET GLUCOSAMINE SULPHCARTIFER/AV.PER2TABLETS GLUCOSAMINE SULPSUSTALIV SACHETS - GLUCOSAMINE SULPHATE | $1.2M | 1 | 8.7% |
| 5 | TROIKAA PHARMACEUTICALS LIMITED CARTILAMINE PLUS GLUCOSAMINE AND CHONDRO | $946.1K | 7 | 7.1% |
| 6 | SAVA HEALTHCARE LIMITED | $868.3K | 3 | 6.6% |
| 7 | NIBBLEN LIFE SCIENCES PRIVATE LIMITED GLUCOSAMINE SULPHATE POTASSIUM CHLORIDEGLUCOSAMINE CAPSULES 750MG CARTIPLUS -CARTICARE TABLETS (GLUCOSAMINE SULFATE T | $631.3K | 1 | 4.8% |
| 8 | MMC HEALTH CARE LIMITED GLUCOSAMINE SULPHATE POTASSIUM CHLORIDEGLUCOSAMINE CAPSULES 750MG CARTIPLUS -CARTIPLUS-750/ GLUCOSAMINE | $473.2K | 2 | 3.6% |
| 9 | BIOPLUS LIFE SCIENCES PRIVATE LIMITED GLUCOSAMINE 1178MG TABLETS RAW MATERIALS | $449.2K | 1 | 3.4% |
| 10 | ORGANOSYN LIFE SCIENCES PRIVATE LIMITED | $419.3K | 2 | 3.2% |
| 11 | THE MADRAS PHARMACEUTICALS ARTHOCARE FORTE CAPLETS (GLUCOSAMINE, CHARTHOCARE FORTEARTHOCARE CAPSULES (GLUCOSAMINE HYDROCHL | $374.2K | 3 | 2.8% |
| 12 | VEROS HEALTHCARE PRIVATE LIMITED DOLOARTRISAR GLUCOSAMINE 500MG+CHONDROTDOLOARTRISAR SOFT GEL CAPSULE | $361.9K | 1 | 2.7% |
| 13 | PHRIA PHARMAOTECH PRIVATE LIMITED KONDRO NOVA CAPSULES (GLUCOSAMINE SULPHAKONDRO NOVA CAPSULES GLUCOSAMINE SULPHAKONDRO NOVA CAPUSLES GLUCOSAMINE SULPHA | $314.2K | 1 | 2.4% |
| 14 | AUROCHEM PHARMACEUTICALS (INDIA) PRIVATELIMITED CARTILAMINE PLUS GLUCOSAMINE AND CHONDRO | $223.3K | 2 | 1.7% |
| 15 | SAGA LIFESCIENCES LIMITED | $198.4K | 1 | 1.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Glucosamine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Panacea Biotec Limited | Warning Letter issued in | Yes | Yes | Not verified | Received FDA Warning Letter in September 2020; holds WHO-GMP and EU GMP certific |
| Medreich Limited | Approved | Yes | Yes | Not verified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
| Troikaa Pharmaceuticals Limited | Approved | Yes | Yes | Not verified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
| Sava Healthcare Limited | Approved | Yes | Yes | Not verified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
| Aurochem Pharmaceuticals (India) Private Limited | Approved | Yes | Yes | Not verified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
| Saga Lifesciences Limited | Approved | Yes | Yes | Not verified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
| The Madras Pharmaceuticals | Approved | Yes | Yes | Not verified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
| Veros Healthcare Private Limited | Approved | Yes | Yes | Not verified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 8 leading Glucosamine exporters from India. 7 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Glucosamine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, which is home to over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. This concentration of expertise and infrastructure makes Hyderabad a key player in the pharmaceutical sector.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with major companies such as Zydus Cadila and Torrent Pharmaceuticals operating in this region. The well-established infrastructure and regulatory environment support a robust manufacturing ecosystem, particularly for finished dosage forms.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the export of pharmaceuticals to global markets. The region is home to several pharmaceutical companies that leverage the logistical advantages and proximity to international shipping routes to distribute products worldwide.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, partly due to favorable tax incentives. The region houses over 1,000 pharmaceutical manufacturing units, making it one of the largest pharmaceutical clusters in Asia. Companies benefit from cost advantages and a supportive regulatory environment, contributing to its prominence in the industry.
5Sourcing Recommendations
- Evaluate Supplier Capabilities: Assess the production capacities and quality standards of suppliers in Hyderabad and Ahmedabad-Vadodara, given their specialization in APIs and formulations, respectively.
- Leverage Export Infrastructure: Utilize the logistical advantages of the Mumbai-Thane-Raigad region for efficient distribution of glucosamine products to international markets.
- Consider Cost Benefits: Explore manufacturing opportunities in Baddi-Nalagarh to take advantage of potential cost savings due to tax incentives and established manufacturing facilities.
- Ensure Regulatory Compliance: Verify that all suppliers adhere to the regulatory standards set by the Central Drugs Standard Control Organisation (CDSCO) and other relevant authorities to ensure product quality and compliance.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Glucosamine exporters from India
Panacea Biotec Pharma Limited — Mankind Pharma acquires Panacea Biotec's domestic formulations brands
In February 2022, Mankind Pharma Limited acquired several pharmaceutical formulations brands from Panacea Biotec Pharma Limited and Panacea Biotec Limited in India and Nepal. This acquisition aimed to strengthen Mankind Pharma's presence in the domestic market. - IMPACT: The divestiture of domestic formulations brands by Panacea Biotec may have led to a strategic shift in their export focus, potentially affecting their Glucosamine export operations.
Impact: The divestiture of domestic formulations brands by Panacea Biotec may have led to a strategic shift in their export focus, potentially affecting their Glucosamine export operations.
Mankind Pharma Limited — Mankind Pharma acquires Daffy and Combihale brands from Dr. Reddy's Laboratories
In February 2022, Mankind Pharma Limited acquired the dermatology brand Daffy and the respiratory brand Combihale from Dr. Reddy's Laboratories. This acquisition was part of Mankind Pharma's strategy to diversify its therapeutic portfolio. - IMPACT: While this acquisition does not directly involve Glucosamine, Mankind Pharma's expanded portfolio may influence market dynamics and competitive positioning in related pharmaceutical segments.
Impact: While this acquisition does not directly involve Glucosamine, Mankind Pharma's expanded portfolio may influence market dynamics and competitive positioning in related pharmaceutical segments.
Mankind Pharma Limited — Mankind Pharma launches IPO with existing investors selling shares
In April 2023, Mankind Pharma Limited launched its initial public offering (IPO), with existing investors selling shares worth ₹4,326 crore. This move aimed to raise capital for the company's growth initiatives. - IMPACT: The capital raised through the IPO may enable Mankind Pharma to invest in expanding its product lines, potentially affecting the competitive landscape for Glucosamine exports.
Impact: The capital raised through the IPO may enable Mankind Pharma to invest in expanding its product lines, potentially affecting the competitive landscape for Glucosamine exports.
Common Questions — Glucosamine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which glucosamine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, PANACEA BIOTEC PHARMA LIMITED leads with 41 recorded shipments worth $1.8M. MEDINOMICS HEALTH CARE PRIVATE LIMITED (24 shipments) and MEDREICH LIMITED (27 shipments) are also established high-volume exporters.
Q How many glucosamine manufacturers are there in India?
India has 118 active glucosamine exporters with a combined export market of $13.3M across 657 shipments to 65 countries. The top 5 suppliers hold 54.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for glucosamine from India?
Average FOB unit price: $5.65 per unit, ranging from $0.03 to $357.65. Average shipment value: $20.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 118 verified Indian exporters of Glucosamine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 657 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 65 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
657 Verified Shipments
118 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists